By Measuring The Ability To Specifically Bind A Target Molecule (e.g., Antibody-antigen Binding, Receptor-ligand Binding, Etc.) Patents (Class 506/9)
  • Patent number: 11519845
    Abstract: The present invention relates to a device (10) for use in fluid sample analysis. It is described to position (310) a top part (20) of the device (10) adjacent to a base part (30) of the device so as to define a fluidic receiving region in between, the top part being provided with a through opening fluidly connected to the fluidic receiving region, and the bottom part being provided with a radiation window adjacent to the fluidic receiving region. A fluidic sample is supplied (320) through the opening (24). The fluidic sample is moved laterally (330) in the fluid receiving region without the use of an intermediary membrane between the top part and the base part. A radiation is emitted (340) to the fluid receiving region. A radiation is detected (350) that is reflected by the device. A presence of the fluidic sample is determined (360) on the basis of a measured reflectance value based on the detected radiation.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: December 6, 2022
    Assignee: Siemens Healthineers Nederland B.V.
    Inventors: Alexander Van Reenen, Markus Hendrikus Van Roosmalen, Hendrik Sibolt Van Damme
  • Patent number: 11513123
    Abstract: This invention provides methods, reagents, and diagnostic and prognostic markers useful for minimally invasive identification, diagnosis, and therapeutic intervention in individuals with colorectal cancers, or individuals who may be susceptible to developing colorectal cancers.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: November 29, 2022
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Melanie Mae Ivancic, Michael Richard Sussman, William Franklin Dove, Amy Ann Irving, Jennifer Kathleen Pleiman, Edward Lee Huttlin, Xiaodi Chen, Adrian Daniel Hegeman, Mark Reichelderfer, Gregory D. Kennedy, Perry J. Pickhardt
  • Patent number: 11505826
    Abstract: The present disclosure is directed to a single-end sequencing method for improved detection of genomic rearrangements such as deletions, insertions, inversions, and translocations that are present in a polynucleotide. A first priming event allows for sequencing of a target sequence, and a second priming event on an adapter allows for identification of the sequences amplified and tagged by selective amplification. The combination of priming events in the same direction facilitates read alignment and the identification of any genomic rearrangements.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: November 22, 2022
    Assignee: Agilent Technologies, Inc.
    Inventors: Margherita Corioni, Douglas N Roberts
  • Patent number: 11499196
    Abstract: Disclosed herein are methods and systems of utilizing sequencing reads for detecting and quantifying the presence of a tissue type or a disease type in cell-free DNA prepared from blood samples.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: November 15, 2022
    Assignees: The Regents of the University of California, University of Southern California
    Inventors: Xianghong Jasmine Zhou, Shuli Kang, Steven Dubinett, Wenyuan Li, Qingjiao Li
  • Patent number: 11492666
    Abstract: A method for determining the presence of an allele, including (a) binding a polymerase to a double stranded nucleic acid that includes a primer hybridized to a template, the template including a first allele of a locus; (b) adding a nucleotide to the primer via catalytic activity of the polymerase, thereby producing an extended nucleic acid; (c) dissociating the polymerase from the extended nucleic acid; (d) detecting dissociation of the polymerase from the extended nucleic acid; and (e) comparing the dissociation of the polymerase from the extended nucleic acid to dissociation of the polymerase from a second double stranded nucleic acid, the second double stranded nucleic acid including a primer hybridized to the same position of the locus as the primer of the extended nucleic acid.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: November 8, 2022
    Assignee: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
    Inventors: Denis Malyshev, Sean Stromberg
  • Patent number: 11492602
    Abstract: The present invention provides a gene including an M13 p5 expressing cassette, which includes a promoter, a ribosome binding site (RBS) and a protein 5 (p5) coding region, wherein at least one base of sequences between the RBS and the p5 coding region is mutated. Using this gene may increase production of single-stranded DNA.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: November 8, 2022
    Assignee: Korea University Research and Business Foundation
    Inventors: Min Kyu Oh, Dong June Ahn, Seungwoo Lee, Bo Young Lee, Jun Min Lee, Jae Won Lee
  • Patent number: 11491483
    Abstract: Devices for high throughput cell electroporation include a trapping component that at least partially defines an upper boundary of a microfluidic chamber. A cell trap array is patterned on the underside of the trapping component, and a channeling component is positioned beneath the trapping component. The channeling component includes a vertically oriented nanochannel array. The trapping component and the channeling component are positioned such that a given nanochannels is positioned beneath a cell trap. During use, fluid flow holds trapped cells in secure contact with the nanochannels beneath the cell trap. The device further includes upper and lower electrode layers for generating an electric field to electroporate trapped cells via the nanochannel array. A reservoir positioned beneath the channeling component can be filled transfection reagent solution. During electroporation, the transfection reagent solution travels through the nanochannel array during to transfect the trapped cells.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: November 8, 2022
    Assignee: Ohio State Innovation Foundation
    Inventors: L. James Lee, Junfeng Shi
  • Patent number: 11493520
    Abstract: The invention relates to assays for nucleosome remodeling activity using functionalized recombinant mononucleosomes. The functionalized recombinant mononucleosomes comprise a histone octamer comprising recombinant histone H2A, H2B, H3 and H4 proteins and a DNA template comprising a nucleosome positioning sequence that effectively positions the histone octamer and a signal site. The invention further relates to methods of using the assay to quantify enzymatic activity of remodeling enzymes and identifying modulators of remodeling enzyme activity.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: November 8, 2022
    Assignee: EpiCypher, Inc.
    Inventors: Michael-Christopher Keogh, Martis William Cowles, Matthew Fruge Whelihan
  • Patent number: 11484581
    Abstract: Provided herein, are methods of treating cancer in dogs using personalized cancer vaccines comprising peptides having frameshift mutations caused by errors in transcription and splicing of an mRNA.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: November 1, 2022
    Assignee: Arizona Board of Regents on Behalf of Arizona State University
    Inventors: Stephen Albert Johnston, Luhui Shen
  • Patent number: 11479817
    Abstract: The present invention relates to a method for discriminating an operationally tolerant (TOL) subject from a non-operationally tolerant (STA) subject, comprising the following steps: i) establishing a composite score of tolerance (cSoT) with the expression levels of six genes in a biological sample obtained from said subject and two clinical parameters; wherein said six genes are ID3, AKR1C3, CD40, CTLA4, TCL1A and MZB1, and wherein said cSoT is established by the following formula: cSoT = ? i n ? = ? i × Exprs + ? test ? ? time × age test ? ? time + ? trans ? ? time × age trans ? ? time + intercept - scaling ? ? coefficient ii) comparing this cSoT with a predetermined reference value; and iii) concluding that the subject is TOL when the cSoT is higher than the predetermined reference value or concluding that the subject is STA when the cSoT is lower than the predetermined reference value.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: October 25, 2022
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale, Université de Nantes, Centre Hospitalier Universitaire de Nantes, Centre National de la Recherche Scientifique
    Inventors: Richard Danger, Sophie Brouard, Magali Giral, Gérard Ramstein
  • Patent number: 11474105
    Abstract: The present invention provides a method of diagnosing endometriosis and/or infertility in a subject, comprising: a) obtaining a sample from the subject; b) detecting a level of expression of a SIRT1 gene and/or protein in the sample; c) detecting a level of expression of a BCL6 gene and/or protein in the sample; d) comparing the level of expression detected in (b) with the level of expression of a SIRT1 gene and/or protein in a sample obtained from a control subject or a population of control subjects; e) comparing the level of expression detected in (c) with the level of expression of a BCL6 gene and/or protein in a sample obtained from a control subject or a population of control subjects; and f) diagnosing the subject as having infertility when the subject has a level of expression of the SIRT1 gene and/or protein greater than the level of expression of the SIRT1 gene and/or protein of the control subject or population of control subjects and also has a level of expression of the BCL6 gene and/or protein t
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: October 18, 2022
    Assignees: The University of North Carolina at Chapel Hill, Upstate Affiliate Organization, Board of Trustees of Michigan State University
    Inventors: Steven L. Young, Bruce Arthur Lessey, Jae Wook Jeong
  • Patent number: 11458995
    Abstract: Among other things, techniques are described for screening and monitoring the health of a vehicle user including receiving sensor data produced by a sensor at the vehicle, processing the sensor data to determine at least one health condition of the user of the vehicle, and in response to determining the at least one health condition, executing a vehicle function selected from a plurality of vehicle functions based on the at least one health condition.
    Type: Grant
    Filed: July 28, 2020
    Date of Patent: October 4, 2022
    Assignee: Motional AD LLC
    Inventors: Eric Wolff, Abhimanyu Singh, Linh Pham
  • Patent number: 11459623
    Abstract: The present invention relates to a method for detecting or quantifying deoxyribonucleic acid (DNA) of human immunodeficiency virus 2 (HIV-2) in a sample containing DNA comprising: a) performing a real-time polymerase chain reaction (PCR) on the sample, or a fraction thereof comprising DNA, with at least two sets of primers and probe each respectively comprising two primers and a labeled probe for the detection or quantification of HIV-2 DNA, at least one of the sets is selected from the group consisting of: a set comprising a primer comprising or consisting of a sequence SEQ ID NO: 1 or a sequence having al least 90% identity to SEQ ID NO: 1, a primer comprising or consisting of a sequence SEQ ID NO: 2 or a sequence having 90% identity to SEQ ID NO: 2 or the complement of these sequences, and a labeled probe comprising or consisting of a sequence SEQ ID NO: 3, or a sequence having at least 90% identify to SEQ ID NO: 3 or the complement of these sequences, and a set comprising a primer comprising or consisting
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: October 4, 2022
    Assignees: UNIVERSITÉ PARIS CITÉ, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, CHU DE ROUEN, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE DE ROUEN, UNIVERSITÉ PARIS NORD
    Inventors: Adeline Melard, Mélanie Bertine, Véronique Avettand Fenoel, Florence Damond, Christine Rouzioux, Diane Descamps, Marie Gueudin, Jean-Christophe Plantier
  • Patent number: 11459621
    Abstract: The present disclosure is in the field of plant breeding and disease resistance. The disclosure provides methods for breeding corn plants having late wilt (LW) resistance using marker-assisted selection. The disclosure further provides corn germplasm resistant to LW. The disclosure also provides markers associated with LW resistance loci for introgressing these loci into elite germplasm in a breeding program, thus producing novel LW resistant germplasm.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: October 4, 2022
    Assignee: Monsanto Technology LLC
    Inventors: Rakesh B, Sunil Kumar Biradar, Franck Jean Chopin, Romain Fouquet, Sonali Dilip Gandhi, Erappa Gangappa, Veeresh RP Gowda, Yule Pan, Jean-Luc Pellet, Dharanendra Swamy, Gonzalo Torres, Chongqing Xie
  • Patent number: 11458805
    Abstract: An air quality system for a vehicle includes a chemical detection apparatus including a plurality of nanofiber chemical sensors for sensing a plurality of airborne materials in a compartment of the vehicle. The plurality of nanofiber chemical sensors are configured to adjust a characteristic electrical signal in response to changes in the presence of the plurality of airborne materials. The chemical detection apparatus further includes a processor coupled to the nanofiber chemical sensor, wherein the processor is configured to monitor the characteristic electrical signals from the nanofiber chemical sensors and generate a detection signal in response to a change in the characteristic electrical signals. The processor is in communication with a controller configured to control at least one vehicle system in response to the detection of one or more of the airborne materials.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: October 4, 2022
    Assignee: GENTEX CORPORATION
    Inventors: Matthew W. Remijn, Darin D. Tuttle, Kurtis L. Geerlings, Douglas W. Later, Benjamin R. Bunes
  • Patent number: 11459602
    Abstract: The present invention relates to methods for the identification of methylated cytosines in a population of double stranded DNA molecules. The invention also relates to adapters and kits for synthesizing said adapters as well as to double stranded DNA libraries obtained by the methods of the invention.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: October 4, 2022
    Assignees: Fundadó Privada Institut De Medicina Predictiva I, Personalitzada Del Cáncer Llorenç Coll Mulet
    Inventors: Llorenç Coll Mulet, Miguel A. Peinado Morales
  • Patent number: 11458191
    Abstract: The present disclosure provides compositions and methods for targeting a Ras antigen to, for example, treat or prevent cancer. Disclosed embodiments include binding proteins, such as a T cell receptor or a chimeric antigen receptor, that bind to a Ras antigen:HLA complex. Polynucleotides encoding such binding protein can introduced into a host cell, such as a T cell, and the cell can be used in immunotherapy for treating various cancers. Also provided are immunogenic polypeptides that can be useful to, for example, induce an immune response against a mutated Ras or to identify a binding protein that binds to a Ras antigen.
    Type: Grant
    Filed: December 8, 2021
    Date of Patent: October 4, 2022
    Assignee: FRED HUTCHINSON CANCER CENTER
    Inventors: Rachel Perret, Philip D. Greenberg, Thomas M. Schmitt, Aude G. Chapuis, Ingunn M. Stromnes, Tijana Martinov
  • Patent number: 11453908
    Abstract: Disclosed herein are methods and compositions such as primers, primer pairs, and kits for typing KIR2DL1, KIR2DL2, Sand KIR2DL3 alleles. The compositions and methods disclosed herein are useful in the selection of most appropriate donors for HCT.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: September 27, 2022
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Katharine Hsu, Jean-Benoit Le Luduec
  • Patent number: 11453909
    Abstract: Disclosed herein are modified polymerase compositions exhibiting altered polymerase activity, which can be useful in a variety of biological applications. Also disclosed herein are methods of making and using such compositions. In some embodiments, the compositions exhibit altered properties that can enhance their utility in a variety of biological applications. Such altered properties, can include, for example, altered nucleotide binding affinities, altered nucleotide incorporation kinetics, altered photostability and/or altered nanoparticle tolerance, as well as a range of other properties as disclosed herein.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: September 27, 2022
    Assignee: Life Technologies Corporation
    Inventors: Stephen P. Hendricks, Michael Phelan, Marian Peris, Cheng-Yao Chen, Daniel Mazur, Xinzhan Peng, Amy Castillo
  • Patent number: 11453715
    Abstract: The present invention relates to methods for treating and preventing Staphylococcus aureus infection and/or a condition resulting from a S. aureus infection in a subject that involves administering compositions that inhibit S. aureus interaction with CXCR1/CXCR2 and DARC cellular receptors. The present invention further relates to novel compositions for carrying out these and other methods.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: September 27, 2022
    Assignee: NEW YORK UNIVERSITY
    Inventors: Victor J. Torres, Tamara Reyes-Robles, Francis Alonzo, III
  • Patent number: 11441181
    Abstract: A use of at least one miRNA, said at least one miRNA being miR-124, as a biomarker, in particular of a viral infection, or of an efficacy of a therapeutic treatment of said viral infection.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: September 13, 2022
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIE
    Inventors: Jamal Tazi, Didier Scherrer, Aude Garcel, Noëlie Campos, Romain Najman, Florence Mahuteau-Betzer
  • Patent number: 11434267
    Abstract: The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimer's Disease or frontotemporal dementia.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: September 6, 2022
    Assignee: The Regents of the University of California
    Inventors: John K. Bielicki, Jan Johansson, Waleed Danho
  • Patent number: 11435334
    Abstract: To give reliability to statistical data on samples as discrete materials, a required sample-number determination device includes: a required sample number for each class acquisition unit configured to acquire a required sample number for each class Ni by the following Equation (1) based on a proportion P{circumflex over (?)}i, that is a ratio of the number of samples in each class to the number of the samples in the population; a temporary required sample number acquisition unit configured to acquire a temporary required sample number Nr, which may be a maximum value among the required sample numbers for each class Ni; and a required sample number determination unit configured to determine the temporary required sample number Nr as a true required sample number when the sample number reaches the temporary required sample number Nr or more, [ Mathematical ? ? 1 ] ? N i = ( K P ? i ) 2 ? P ^ i ? ( 1 - P ^ i ) ( 1 ) in Equation (1), ?i denotes a
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: September 6, 2022
    Assignee: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventors: Takao Ueda, Tatsuya Oki
  • Patent number: 11434522
    Abstract: A method of determining the epigenetic chromosome interactions which are relevant to a companion diagnostic.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: September 6, 2022
    Assignee: Oxford Biodynamics PLC
    Inventors: Ewan Hunter, Aroul Ramadass, Alexandre Akoulitchev
  • Patent number: 11427859
    Abstract: Provided for herein is a method for detecting the presence of a nucleic acid target molecule in a biological sample. In certain aspects, the method comprises contacting a test sample that comprises (i) a biological sample comprising a nucleic acid target molecule and (ii) an osmylated single-stranded oligonucleotide probe comprising at least one pyrimidine residue covalently bonded to a substituted or unsubstituted Osmium tetroxide (OsO4)-2,2?-bypyridine group (OsBp group).
    Type: Grant
    Filed: September 3, 2021
    Date of Patent: August 30, 2022
    Inventor: Anastassia Kanavarioti
  • Patent number: 11430545
    Abstract: Various methods, systems, computer readable media, and graphical user interfaces (GUIs) are presented and described that enable a subject, doctor, or user to characterize or classify various types of cancer precisely. Additionally, described herein are methods, systems, computer readable media, and GUIs that enable more effective specification of treatment and improved outcomes for patients with identified types of cancer. Some embodiments of the methods, systems, computer readable media, and GUIs described herein comprise obtaining RNA expression data and/or whole exome sequencing (WES) data for a biological sample; determining a molecular-functional (MF) profile for the subject at least in part by determining first and second visual characteristics for first and second GUI elements using the data; generating a personalized GUI personalized to the subject using the first and second visual characteristics; and presenting the generated personalized GUI to a user.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: August 30, 2022
    Assignee: BostonGene Corporation
    Inventors: Alexander Bagaev, Feliks Frenkel, Nikita Kotlov, Ravshan Ataullakhanov, Olga Isaeva
  • Patent number: 11426423
    Abstract: The methods and assays described herein relate to detection, diagnosis, and treatment of lung cancer, e.g., by detecting the level of expression of certain miRNAs described herein and/or by therapeutically increasing the level of those miRNAs.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: August 30, 2022
    Assignee: Trustees of Boston University
    Inventors: Ana Brandusa Pavel, Joshua David Campbell, Marc Elliott Lenburg, Avrum Elliot Spira
  • Patent number: 11421265
    Abstract: A method of analyzing a tumor sample comprising: (a) acquiring a library comprising a plurality of tumor members from a tumor sample; (b) contacting the library with a bait set to provide selected members; (c) acquiring a read for a subgenomic interval from a tumor member from said library; (d) aligning said read; and (e) assigning a nucleotide value (e.g., calling a mutation) from said read for the preselected nucleotide position, thereby analyzing said tumor sample.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: August 23, 2022
    Assignee: FOUNDATION MEDICINE, INC.
    Inventors: Doron Lipson, Geoffrey Alan Otto, Alexander Nevin Parker, Philip James Stephens, Sean R. Downing, Mima Jarosz, Mikhail G. Shapiro, Roman Yelensky
  • Patent number: 11421212
    Abstract: The invention is directed to non-natural yeast able to secrete significant amounts of glucoamylase into a fermentation media. The glucoamylase can promote degradation of starch material generating glucose for fermentation to a desired bioproduct, such as ethanol. The glucoamylase can be provided in the form of a glucoamylase fusion protein having secretion signal that is: derived from at least AA 1-19 of SEQ ID NO: 73, (ii) an amino acid sequence of at least AA 1-19 of SEQ ID NO: 74, (iii) SEQ ID NO: 77 (An aa), (iv) SEQ ID NO: 75 (Sc IV), (v) SEQ ID NO: 76 (Gg LZ), or (vi) SEQ ID NO: 78(Hs SA).
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: August 23, 2022
    Assignee: CARGILL, INCORPORATED
    Inventors: Christopher K. Miller, Gregory Michael Poynter, Amit Vas
  • Patent number: 11421284
    Abstract: The present invention features methods, devices, and kits for detecting expression in a patient having cancer or determining responsive of a patient having cancer to a treatment, such as irofulven. The invention further includes methods of treating a patient having cancer by administering, e.g., irofulven.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: August 23, 2022
    Assignee: Allarity Therapeutics Europe ApS
    Inventor: Steen Knudsen
  • Patent number: 11402373
    Abstract: The present invention relates to detection molecules comprising at least one binding molecule, at least one linker and at least one label, and detection methods making use of same. The invention provides a high-throughput method for detection, isolation and/or identification of specific entities or cells.
    Type: Grant
    Filed: February 10, 2022
    Date of Patent: August 2, 2022
    Assignees: Immudex ApS, Herlev Hospital
    Inventors: Henrik Pedersen, Søren Jakobsen, Sine Reker Hadrup, Amalie Kai Bentzen, Kristoffer Haurum Johansen
  • Patent number: 11401560
    Abstract: Disclosed are a set of genes for bladder cancer detection and their use. The set of genes includes the following 32 genes: CA9 gene, CDK1 gene, CTSE gene, DMBT1 gene, ERBB2 gene, HOXA13 gene, IGF2 gene, CXCR2 gene, MAGEA3 gene, MDK gene, MMP1 gene, MMP12 gene, RBP2 gene, CCL18 gene, SNAI2 gene, VEGFA gene, MFAP5 gene, SGK2 gene, WFDC2 gene, POSTN gene, NPFFR2 gene, ANXA10 gene, CTAG2 gene, ZDHHC2 gene, KRT20 gene, PPP1R14D gene, FGD3 gene, AHNAK2 gene, SEMA3D gene, ZNF707 gene, LOC100652931 gene, and LINC00565 gene. After clinical validation, the kit provided by the present invention is used to detect bladder cancer with a high accuracy rate and objective interpretation of results. Meanwhile, as a non-invasive detection, the compliance of patients is greatly improved comparing with the existing cystoscopy, which has an important clinical significance for the early detection and postoperative monitoring of bladder cancer.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: August 2, 2022
    Assignee: HANGZHOU CANHELP GENOMICS TECHNOLOGY CO. LTD.
    Inventors: Qinghua Xu, Dingwei Ye, Qifeng Wang, Chengshu Chen, Jinying Chen, Yifeng Sun, Wanli Ren, Hongying Wang, Yiwang Wu, Tao Huo
  • Patent number: 11397882
    Abstract: Disclosed herein are methods and systems for determining the numbers of targets. In some embodiments, the method comprise: stochastically barcoding targets using stochastic barcodes; obtaining sequencing data; for one or more of the targets: counting the number of molecular labels with distinct sequences associated with the target in the sequencing data; identifying clusters of molecular labels of the target using directional adjacency; collapsing the sequencing data using the clusters of molecular labels of the target identified; and estimating the number of the target.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: July 26, 2022
    Assignee: Becton, Dickinson and Company
    Inventors: Jue Fan, Jennifer Tsai, Eleen Shum, Lisha Deng, Glenn K. Fu
  • Patent number: 11397182
    Abstract: The present invention is directed to a method for identifying an individual who is at risk for developing metastatic liver disease that involves measuring, in a sample isolated from the individual, exosomal levels of one or more markers of metastatic liver disease. Kits for carrying out this method are also disclosed. The present invention also relates to a method of preventing metastatic liver disease in an individual who are at risk for developing the disease that involves administering one or more inhibitors of liver pre-metastatic niche formation.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: July 26, 2022
    Assignee: CORNELL UNIVERSITY
    Inventors: David C. Lyden, Bruno Costa Da Silva
  • Patent number: 11398296
    Abstract: Methods, sample vessels, and instruments are provided for melting curve analysis. A sample is amplified by thermal cycling the sample well between at least an annealing temperature and a denaturation temperature through n cycles, where each cycle includes an in-cycle denaturation step. Fluorescent data is collected during the in-cycle denaturation step of n cycles where n is at least two. Then a composite melting curve is generated using the fluorescent data collected during the denaturation step of each of the n cycles, and the sample is called using the composite melting curve, where the call is a positive or a negative call.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: July 26, 2022
    Assignee: BIOFIRE DIAGNOSTICS, LLC
    Inventors: Benjamin William Galvin, Thomas Charles Robbins, Charles Benjamin Cox
  • Patent number: 11377690
    Abstract: The subject of the invention is a method for making an in vitro prognosis of severity for a patient in septic shock, including the following steps: (i) the level of expression of the expression product of at least one gene chosen from the lilrb2 and lilrb1 genes is measured in vitro on the basis of a biological sample taken from the patient, (ii) the level of expression of the expression product of the at least one gene is compared with a control level of expression, of the expression product of the same gene, with a good prognosis of severity, in which a level of expression of the expression product of the at least one gene below the control level of expression indicates a poor prognosis of severity for the patient, and also a kit for implementing the method.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: July 5, 2022
    Assignees: BIOMERIEUX, HOSPICES CIVILS DE LYON
    Inventors: Marie-Angelique Cazalis, Maud Tournoud, Fabienne Venet, Alain Lepape, Guillaume Monneret
  • Patent number: 11371096
    Abstract: The invention relates to methods and kits for diagnosing and/or treating appendicitis in a subject, comprising performing one or more assays configured to detect one or more biomarkers on a body fluid sample obtained from the subject to provide one or more assay result(s) and correlating the assay result(s) to the occurrence or nonoccurrence of appendicitis in the subject or likelihood of the future outcome to the subject.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: June 28, 2022
    Assignee: The George Washington University A Congressionally Chartered Not-For-Profit Corporation
    Inventors: Lakhmir S. Chawla, Timothy A. McCaffrey
  • Patent number: 11365452
    Abstract: The present invention relates to markers being capable of predicting or diagnosing the risk of metabolic syndrome or metabolic syndrome-related diseases and their use. More particularly, the present invention relates to a composition, a kit and a method for predicting or diagnosing the risk of metabolic syndrome or metabolic syndrome-related diseases by detecting Neisseria spp., Granulicatella spp., and/or Peptococcus spp. in a test sample.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: June 21, 2022
    Assignees: KOBIOLABS, INC., SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: GwangPyo Ko, Jiyeon Si, Cheonghoon Lee
  • Patent number: 11366120
    Abstract: The invention relates to the measurement and profiling of proteins including phosphoproteins from cells in particular the measurement and profiling of phosphoproteins involved in cancer.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: June 21, 2022
    Inventor: Xiaolian Gao
  • Patent number: 11365449
    Abstract: This application provides a kit or a device for the detection of early pancreatic cancer or a pancreatic cancer precursor lesion, comprising a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting early pancreatic cancer or a pancreatic cancer precursor lesion, comprising measuring an expression level(s) of the miRNA(s) in vitro.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: June 21, 2022
    Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
    Inventors: Junpei Kawauchi, Hiroko Sudo, Satoko Kozono, Atsushi Ochiai, Motohiro Kojima
  • Patent number: 11360087
    Abstract: Use of (i) an anti-CD3 antibody, (ii) an anti-CD56 antibody, (iii) an anti-CD14 antibody, (iv) an anti-CD38 antibody, (v) an anti-CD45 antibody, (vi) an anti-CD90 antibody, (vii) an anti-CD135 antibody, (viii) an anti-CD10 antibody, (ix) an anti-CD11c antibody, (x) an anti-CD19 antibody, (xi) an anti-CD34 antibody, (xii) an anti-CD45RA antibody, (xiii) an anti-CD7 antibody, (xiv) an anti-CD71 antibody, (xv) an anti-CD41/CD61 complex antibody or an anti-CD41 antibody and/or an anti-CD61 antibody (xvi) an anti-CD33 antibody and/or an anti-CD66b antibody, for identifying hematopoietic cell subtypes in an isolated sample, determining the relative frequency of hematopoietic cell subtypes in an isolated sample and/or quantifying the number of cells within hematopoietic cell subtypes in an isolated sample, wherein each of (i) to (xvi) is labelled with a different fluorochrome, wherein when (xvi) is an anti-CD33 antibody and an anti-CD66b antibody, the anti-CD33 antibody and anti-CD66b are labelled with the same fluo
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: June 14, 2022
    Assignees: Ospedale San Raffaele S.R.L., Fondazione Telethon
    Inventors: Luca Basso-Ricci, Luca Biasco, Alessandro Aiuti
  • Patent number: 11359244
    Abstract: Methods are provided for detecting and quantitating molecules using fluidics. In preferred embodiments, the methods comprise analyzing blood to detect the presence of circulating DNA or cells from a fetus or tumor.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: June 14, 2022
    Assignee: Bionano Genomics, Inc.
    Inventors: Han Cao, Alex R. Hastie, Ernest Tsz-Tsun Lam
  • Patent number: 11360097
    Abstract: The present invention relates to biomarkers and diagnostic and prognostic methods for vascular diseases. In particular, proteins of platelet-derived exosomes have been identified as biomarkers that can be used to detect platelet activation associated with pathogenesis of vascular diseases, including cardiovascular and cerebrovascular diseases. The invention also provides compositions for detecting biomarkers as well as compositions and methods useful for treating vascular diseases.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: June 14, 2022
    Inventor: Edward J Goetzl
  • Patent number: 11352661
    Abstract: The invention provides a device, method, and system for high throughput detection of nucleic acid expression in individual cells. Cells are encapsulated in aqueous microdroplets which are merged with a biocompatible matrix, allowing on-chip fluorescence in situ hybridization on both adherent and non-adherent cells. The invention also provides multiplexed detection of nucleic acids, proteins, and cellular activity. The device and methods can be used to assess cellular interactions and to test the effects of antitumor agents.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: June 7, 2022
    Assignee: Northeastern University
    Inventors: Saheli Sarkar, Tania Konry
  • Patent number: 11353418
    Abstract: According to one embodiment, a nucleic acid reaction tool includes a support having a first surface, a covering body having a second surface, and a groove opened on the second surface, and a primer set. The covering body is in contact with the support to form a reaction space surrounded by the first surface and the groove. The groove includes, on an inner surface of the reaction space, rising surfaces opposed to each other, and a rear surface connecting one end of the side surfaces, and a primer fixing region to which the primer set is fixed, the primer fixing region being located at a corner where the one end of the side surfaces connected to the rear surface in the reaction space.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: June 7, 2022
    Assignee: KABUSHIKI KAISHA TOSHIBA
    Inventors: Koji Hashimoto, Keiko Ito, Mika Inada
  • Patent number: 11352673
    Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in lung cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in lung cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the lung cancer.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: June 7, 2022
    Inventors: Roger Gomis, Evarist Planet
  • Patent number: 11353457
    Abstract: Compositions and methods for the detection and identification of Tick-Borne Relapsing Fever Borrelia sp. antibodies.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: June 7, 2022
    Assignee: ID-Fish Technology, Inc.
    Inventors: Jyotsna S. Shah, Song Liu
  • Patent number: 11352665
    Abstract: The present invention provides oligonucleotide constructs, sets of such oligonucleotide constructs, and methods of using such oligonucleotide constructs to provide validated sequences or sets of validated sequences corresponding to desired ROIs. Such validated ROIs and constructs containing these have a wide variety of uses, including in synthetic biology, quantitative nucleic acid analysis, polymorphism and/or mutation screening, and the like.
    Type: Grant
    Filed: April 22, 2021
    Date of Patent: June 7, 2022
    Assignee: Prognosys Biosciences, Inc.
    Inventor: Mark S. Chee
  • Patent number: 11345970
    Abstract: Kits and methods are described that are directed to specific and sensitive methods of target nucleic acid detection and more specifically detecting target nucleic acids directly from biological samples. The kits and methods were developed to be easy to use involving a minimum number of steps and giving rapid and consistent results either at point of care or in high throughput situations. The kits and methods utilize in various combinations, reversible inhibitors of kit components, thermolabile enzymes, poloxamers, various salts, indicators and one or more Loop-Mediated Isothermal Amplification (LAMP) primer sets for detecting single and/or multiple targets and variants of the targets including SARS-CoV-2 targets and variants thereof in a single reaction. The kits and methods permit detection of the target nucleic with similar sensitivity regardless of the presence of undefined mutations that may enhance the virulence of cells or viruses containing the undefined mutations.
    Type: Grant
    Filed: August 19, 2021
    Date of Patent: May 31, 2022
    Assignee: New England Biolabs, Inc.
    Inventors: Nathan Tanner, Yinhua Zhang, Eric Hunt, Gregory Patton, Guoping Ren, Zhiru Li, Andrew Barry, Nicole Nichols, Catherine B. Poole, Harriet M. Strimpel, Ivan R. Correa, Jr., Clotilde Carlow, Esta Slayton
  • Patent number: 11346846
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of Metalloproteinase inhibitor 1, Metalloproteinase inhibitor 2, Metalloproteinase inhibitor 4, C—C motif chemokine 15, C—C motif chemokine 18, C—C motif chemokine 23, and/or, C—C motif chemokine 24 as diagnostic and prognostic biomarker assays in renal injuries.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: May 31, 2022
    Assignee: Astute Medical, Inc.
    Inventors: Joseph Anderberg, Paul McPherson, James Patrick Kampf, Kevin Nakamura, Jeff Gray, Thomas Kwan